0001104659-19-032920.txt : 20190530
0001104659-19-032920.hdr.sgml : 20190530
20190530212755
ACCESSION NUMBER: 0001104659-19-032920
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190528
FILED AS OF DATE: 20190530
DATE AS OF CHANGE: 20190530
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Novartis Bioventures Ltd
CENTRAL INDEX KEY: 0001297709
STATE OF INCORPORATION: D0
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38916
FILM NUMBER: 19868382
BUSINESS ADDRESS:
STREET 1: C/O NOVARTIS INTERNATIONAL AG
STREET 2: WSJ-200.220
CITY: CH-4002 BASEL
STATE: V8
ZIP: 0000000000
BUSINESS PHONE: 41-61-324-6210
MAIL ADDRESS:
STREET 1: C/O NOVARTIS INTERNATIONAL AG
STREET 2: WSJ-200.220
CITY: CH-4002 BASEL
STATE: V8
ZIP: 0000000000
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: NOVARTIS AG
CENTRAL INDEX KEY: 0001114448
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38916
FILM NUMBER: 19868383
BUSINESS ADDRESS:
STREET 1: LICHTSTRASSE 35
CITY: BASEL
STATE: V8
ZIP: CH 4056
BUSINESS PHONE: 01141613241111
MAIL ADDRESS:
STREET 1: LICHTSTRASSE 35
CITY: BASEL
STATE: V8
ZIP: CH 4056
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BICYCLE THERAPEUTICS plc
CENTRAL INDEX KEY: 0001761612
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
BUSINESS ADDRESS:
STREET 1: B900 BABRAHAM RESEARCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB22 3AT
BUSINESS PHONE: 011441223261503
MAIL ADDRESS:
STREET 1: B900 BABRAHAM RESEARCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB22 3AT
FORMER COMPANY:
FORMER CONFORMED NAME: BICYCLE THERAPEUTICS Ltd
DATE OF NAME CHANGE: 20181212
4
1
a4.xml
4
X0306
4
2019-05-28
1
0001761612
BICYCLE THERAPEUTICS plc
BCYC
0001297709
Novartis Bioventures Ltd
C/O NOVARTIS INTERNATIONAL AG
WSJ-200.220
CH-4002 BASEL
V8
0000000000
SWITZERLAND
0
0
1
0
0001114448
NOVARTIS AG
LICHTSTRASSE 35
BASEL
V8
CH 4056
SWITZERLAND
0
0
1
0
Ordinary Shares
2019-05-28
4
C
0
893195
A
893195
D
Ordinary Shares
2019-05-28
4
X
0
71450
A
964645
D
Ordinary Shares
2019-05-28
4
C
0
636366
A
1601011
D
Ordinary Shares
2019-05-28
4
P
0
168630
14.00
A
1769641
D
Series A Preferred Shares
2019-05-28
4
C
0
893195
D
Ordinary Shares
893195
0
D
Series A Preferred Shares Warrants
2019-05-28
4
X
0
71450
D
Ordinary Shares
71450
0
D
Series B1 Preferred Shares
2019-05-28
4
C
0
636366
D
Ordinary Shares
636366
0
D
Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.
Upon conversion of all of the Series B1 Preferred Shares into Ordinary Shares in connection with the Issuer's initial public offering, the Warrants became exercisable for Ordinary Shares. The Warrants had an exercise price of a nominal value per share and were exercised immediately prior to completion of the Issuer's initial public offering.
Novartis Bioventures Ltd. /s/ Bart Dzikowski, Secretary of the Board
2019-05-30
/s/ Stephan Sandmeier, Authorized Signatory
2019-05-30
Novartis AG /s/ Bart Dzikowski, Attorney-in-Fact
2019-05-30
/s/ Stephan Sandmeier, Attorney-in-Fact
2019-05-30